ReviewKidney international reports2018
Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome.
Review in Kidney international reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group.Nature reviews. Nephrology · 2021Guideline
- Thromboembolic risk and factor Xa inhibitor use in nephrotic syndrome: a pilot study in a predominantly Hispanic cohort.Clinical kidney journal · 2026Article
- Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome.Kidney medicine · 2025Article
- Current antithrombotic prophylaxis in nephrotic syndrome: results from an Italian survey.Internal and emergency medicine · 2025Article
- Managing Pulmonary Embolism Associated With Renal Vein Thrombosis During Nephrotic Syndrome: Usefulness of Rivaroxaban Level Monitoring.Respirology case reports · 2025Article
- Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists.Kidney international reports · 2025Article
- Venous Thromboembolism Prevention in Nephrotic Syndrome: The Role of Aspirin, Vitamin K Antagonists, and Direct Oral Anticoagulants.Kidney international reports · 2025Review
- Challenges and Opportunities of Direct Oral Anticoagulant (DOAC) Therapy in Complex Clinical Scenarios: A Comprehensive Review and Practical Guide.Journal of clinical medicine · 2025Review
- Prophylactic and Therapeutic Anticoagulation in Nephrotic Syndrome Using Direct Acting Oral Anticoagulants.Kidney international reports · 2025Article
- Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study.Kidney international reports · 2025Article
- Article
- Rivaroxaban for Thromboembolism Prophylaxis in Patients with Nephrotic Syndrome: A Single-Arm, Prospective Study.Kidney diseases (Basel, Switzerland) · 2024Article
- The risk of thromboembolic events in patients with nephrotic syndrome and relatively high albumin levels: a study over 10 years.BMC nephrology · 2024Article
- Membranous nephropathy: pathogenesis and treatments.MedComm · 2024Review
- Thromboembolism in nephrotic syndrome: controversies and uncertainties.Research and practice in thrombosis and haemostasis · 2023Review
- [Diagnosis and treatment of Minimal Change Disease in adults-2023].Wiener klinische Wochenschrift · 2023Article
- Research progress of nephrotic syndrome accompanied by thromboembolism.International urology and nephrology · 2023Review
- Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome.TH open : companion journal to thrombosis and haemostasis · 2022Article
- Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: a report of 21 cases.BMC nephrology · 2022Article
- Nephrotic Syndrome Complications - New and Old. Part 1.Maedica · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report 2 cases of apixaban use as prophylaxis against thromboembolism in the nephrotic syndrome (NS), and review the existing literature on direct-acting oral anticoagulant (DOAC) use in this scenario. Our cases appear to be the first reported use of apixaban as prophylaxis against thromboembolism in NS. We report our systematic review of the existing literature on direct-acting oral anticoagulant (DOAC) use in NS, and discuss theoretical issues relevant to their therapeutic use in this clinical scenario. We searched electronic databases such as OVID, EMBASE, PubMed, and CENTRAL, DARE. The search to identify studies and the application of inclusion and exclusion criteria was performed in duplicate independently. We identified 1 pilot randomized study, 3 case reports, and 3 conference proceedings abstracts relating to DOAC use in NS. These reports all pertain to the treatment of clinically evident thrombosis in NS with rivaroxaban, edoxaban, and dabigatran rather than prophylaxis against thrombosis. Although the existing literature on DOAC use in NS is limited, initial preliminary experience appears promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.